Navigation Links
Trovagene to Present at The MicroCap Conference on April 4, 2017 in New York City
Date:3/27/2017

SAN DIEGO, March 27, 2017 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a precision medicine biotechnology company, today announced that its Chief Executive Officer, Bill Welch, will be presenting at this year's MicroCap Conference on April 4, 2017 at 9:00 AM EDT at the Essex House in New York City.  Bill Welch, and Chief Scientific Officer, Mark Erlander, Ph.D., will also be available to meet with investors during the conference.  

The presentation will be webcast live at http://wsw.com/webcast/microcapconf3/trov and can also be accessed through the investor relations web page at www.trovagene.com.   A replay of the presentation will be available at www.trovagene.com and will be archived for 90 days. 

About Trovagene, Inc.

Trovagene is a biotechnology company developing oncology therapeutics for improved cancer care by leveraging its proprietary Precision Cancer Monitoring® (PCM) technology in tumor genomics.  Trovagene has broad intellectual property and proprietary technology to measure circulating tumor DNA (ctDNA) in urine and blood to identify and quantify clinically actionable markers for predicting response to cancer therapies.  Trovagene offers its PCM technology at its CLIA/CAP – accredited laboratory and plans to continue to vertically integrate its PCM technology with precision cancer therapeutics.  For more information, please visit www.trovagene.com.

Trovagene Contact

Vicki Kelemen
Sr. Director, Communications
858-952-7652
vkelemen@trovagene.com

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/trovagene-to-present-at-the-microcap-conference-on-april-4-2017-in-new-york-city-300429443.html


'/>"/>
SOURCE Trovagene, Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related biology technology :

1. Trovagene to Announce Fourth Quarter and Year End 2016 Financial Results and Accomplishments and Host Conference Call on Wednesday, March 15, 2017
2. Trovagene Enters into Preferred Provider Agreement with Three Rivers Provider Network
3. Trovagene Enters into Preferred Provider Agreement with Fortified Provider Network
4. Trovagene Enters into Agreement with FedMed, Inc. and Significantly Expands Patient Access to Its Precision Cancer Monitoring Platform
5. Trovagene Announces Patent Issuance, Broadening its Precision Cancer Monitoring IP Portfolio
6. Clinical Data for Trovagenes Precision Cancer Monitoring Platform Presented at the European Cancer Congress
7. Trovagene, Inc. Announces Second Quarter 2015 Financial Results
8. Matthew Posard Joins Trovagenes Executive Management Team as Chief Commercial Officer
9. Leader in Targeted Drug Development, Peter Hirth, Ph.D., Joins Trovagenes Scientific Advisory Board
10. Trovagene, Inc. Reports Third Quarter 2013 Financial Results
11. Trovagene to Present at Two Healthcare Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... ... , ... The Conference Forum and The Trout Group ... of upcoming panels and events. The partnership culminates with the 4th Annual IO360° ... York City. , “With our experience in producing the Immuno-Oncology 360° NYC event and ...
(Date:8/14/2017)... ... August 14, 2017 , ... Every year, millions of dollars ... antibody community have recently come together to address this antibody crisis and develop ... , The team at Thermo Fisher Scientific has arranged for ...
(Date:8/11/2017)... Md. , Aug. 11, 2017 /PRNewswire/ ... a New York Times article regarding the ... billion, according to Kalorama Information.  The article, ... App for That"  used information from ... Patient Monitoring & Telemedicine Market  (Sleep, Diabetes, ...
(Date:8/11/2017)... ... 11, 2017 , ... “There is an increasing consumer call ... synthetic ingredients,” said Matt Hundt, President of Third Wave Bioactives. “Combining the strong ... know-how of Biorigin will allow us to bring truly novel fermented ingredient technologies ...
Breaking Biology Technology:
(Date:4/11/2017)... -- Research and Markets has announced the addition of ... offering. ... market to grow at a CAGR of 30.37% during the period ... has been prepared based on an in-depth market analysis with inputs ... growth prospects over the coming years. The report also includes a ...
(Date:4/6/2017)... 6, 2017 Forecasts by Product ... Readers, by End-Use (Transportation & Logistics, Government & Public ... & Fossil Generation Facility, Nuclear Power), Industrial, Retail, Business ... Are you looking for a definitive report on ... ...
(Date:4/5/2017)... 4, 2017 KEY FINDINGS The ... at a CAGR of 25.76% during the forecast period ... primary factor for the growth of the stem cell ... MARKET INSIGHTS The global stem cell market ... and geography. The stem cell market of the product ...
Breaking Biology News(10 mins):